Eli Lilly and Company — Clinical Trial Pipeline

Eli Lilly and Company has 12 registered trials in the index.

Trials (12)

• A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer Phase 2 · Eli Lilly and Company
• A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Phase 2 · Eli Lilly and Company
• A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Phase 2 · Eli Lilly and Company
• A Study of LY2784544 in Participants With Myeloproliferative Neoplasms Phase 2 · Eli Lilly and Company
• Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma Phase 1 · Eli Lilly and Company
• A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers Phase 1 · Eli Lilly and Company
• Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy Phase 2 · Eli Lilly and Company
• A Phase 1 Study of LY2874455 in Participants With Advanced Cancer Phase 1 · Eli Lilly and Company
• Study of IMC-11F8 in Participants With Colorectal Cancer Phase 2 · Eli Lilly and Company
• Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer Phase 2 · Eli Lilly and Company
• Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma Phase 2 · Eli Lilly and Company
• A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer Phase 3 · Eli Lilly and Company

Related landscapes

• Breast Cancer
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma
• Prostate Cancer Metastatic
• Neoplasms, Hematologic

Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.